"use strict";(self.webpackChunkgenomics_docusaurus_new=self.webpackChunkgenomics_docusaurus_new||[]).push([[74],{2721:(e,s,n)=>{n.r(s),n.d(s,{assets:()=>c,contentTitle:()=>l,default:()=>u,frontMatter:()=>o,metadata:()=>i,toc:()=>a});const i=JSON.parse('{"id":"oncology-europe/nsclc_intro","title":"NSCLC as Case Study","description":"NSCLC as Case Study","source":"@site/docs/oncology-europe/nsclc_intro.md","sourceDirName":"oncology-europe","slug":"/oncology-europe/nsclc_intro","permalink":"/datasolutions/oncology-europe/nsclc_intro","draft":false,"unlisted":false,"tags":[],"version":"current","sidebarPosition":3,"frontMatter":{"title":"NSCLC as Case Study","sidebar_position":3,"hide_title":true},"sidebar":"docsSidebar","previous":{"title":"Oncology Landscape - Germany","permalink":"/datasolutions/oncology-europe/germany-hospitals"},"next":{"title":"Actionable Biomarkers & CDx Scope","permalink":"/datasolutions/oncology-europe/nsclc_markers"}}');var r=n(4848),t=n(8453);n(6025);const o={title:"NSCLC as Case Study",sidebar_position:3,hide_title:!0},l=void 0,c={},a=[{value:"NSCLC as Case Study",id:"nsclc-as-case-study",level:2}];function d(e){const s={a:"a",h2:"h2",hr:"hr",li:"li",p:"p",strong:"strong",ul:"ul",...(0,t.R)(),...e.components},{Details:n}=s;return n||function(e,s){throw new Error("Expected "+(s?"component":"object")+" `"+e+"` to be defined: you likely forgot to import, pass, or provide it.")}("Details",!0),(0,r.jsxs)(r.Fragment,{children:[(0,r.jsx)(s.h2,{id:"nsclc-as-case-study",children:"NSCLC as Case Study"}),"\n",(0,r.jsx)(s.hr,{}),"\n",(0,r.jsxs)("div",{style:{textAlign:"justify"},children:[(0,r.jsxs)(s.p,{children:["To bridge incidence with clinical practice, I have chosen ",(0,r.jsx)(s.strong,{children:"advanced non\u2013small cell lung cancer (NSCLC)"})," as a reference to illustrate how biomarker testing translates into concrete companion diagnostic (CDx) workflows, assay requirements, and operational constraints."]}),(0,r.jsxs)(s.p,{children:["This section is based on the ",(0,r.jsx)(s.strong,{children:(0,r.jsx)(s.a,{href:"https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf",children:"NCCN Clinical Practice Guidelines in Oncology (NSCLC)"})}),", which define current standards for molecular testing in advanced disease:"]})]}),"\n",(0,r.jsx)("br",{}),"\n",(0,r.jsxs)(n,{style:{backgroundColor:"#f5f9ff",border:"1px solid #c9ddff",borderRadius:"10px",padding:"1rem 1.2rem"},children:[(0,r.jsx)("summary",{style:{fontWeight:"600",cursor:"pointer"},children:(0,r.jsx)(s.p,{children:"Why NSCLC?"})}),(0,r.jsxs)(s.ul,{children:["\n",(0,r.jsxs)(s.li,{children:["Therapy selection is ",(0,r.jsx)(s.strong,{children:"directly driven by molecular findings"})]}),"\n",(0,r.jsxs)(s.li,{children:["Multiple actionable alterations across ",(0,r.jsx)(s.strong,{children:"DNA and RNA"})]}),"\n",(0,r.jsxs)(s.li,{children:[(0,r.jsx)(s.strong,{children:"Multi-gene profiling is standard"}),", not optional"]}),"\n",(0,r.jsxs)(s.li,{children:[(0,r.jsx)(s.strong,{children:"Repeat testing"})," at progression (often via ctDNA)"]}),"\n",(0,r.jsxs)(s.li,{children:["Turnaround time and tissue constraints are ",(0,r.jsx)(s.strong,{children:"clinically visible"})]}),"\n"]})]}),"\n",(0,r.jsx)("br",{}),"\n",(0,r.jsxs)(n,{style:{backgroundColor:"#f5f9ff",border:"1px solid #c9ddff",borderRadius:"10px",padding:"1rem 1.2rem"},children:[(0,r.jsx)("summary",{style:{fontWeight:"600",cursor:"pointer"},children:(0,r.jsx)(s.p,{children:"What guidelines require"})}),(0,r.jsxs)(s.ul,{children:["\n",(0,r.jsx)(s.li,{children:(0,r.jsx)(s.strong,{children:"NGS multi-gene panel testing"})}),"\n",(0,r.jsx)(s.li,{children:(0,r.jsx)(s.strong,{children:"Single-gene testing discouraged"})}),"\n",(0,r.jsxs)(s.li,{children:[(0,r.jsx)(s.strong,{children:"RNA-aware assays"})," needed for fusion/splice detection"]}),"\n",(0,r.jsx)(s.li,{children:(0,r.jsx)(s.strong,{children:"Tissue efficiency is critical"})}),"\n",(0,r.jsxs)(s.li,{children:[(0,r.jsx)(s.strong,{children:"ctDNA complements tissue"}),", especially at progression"]}),"\n",(0,r.jsxs)(s.li,{children:["Results must be interpreted in light of ",(0,r.jsx)(s.strong,{children:"tumour fraction and assay sensitivity"})]}),"\n"]}),(0,r.jsx)("br",{}),(0,r.jsxs)(s.p,{children:["In brief, NSCLC is defined by a ",(0,r.jsx)(s.strong,{children:"testing strategy"}),", not a single assay."]})]}),"\n",(0,r.jsx)("br",{}),"\n",(0,r.jsxs)(n,{style:{backgroundColor:"#f5f9ff",border:"1px solid #c9ddff",borderRadius:"10px",padding:"1rem 1.2rem"},children:[(0,r.jsx)("summary",{style:{fontWeight:"600",cursor:"pointer"},children:(0,r.jsx)(s.p,{children:"Why this matters for sequencing demand"})}),(0,r.jsxs)(s.ul,{children:["\n",(0,r.jsxs)(s.li,{children:["One test per case is a ",(0,r.jsx)(s.strong,{children:"lower limit"})," (limited biopsy material, resistance, progression monitoring)"]}),"\n",(0,r.jsxs)(s.li,{children:["Demand is better described as ",(0,r.jsx)(s.strong,{children:"tests per patient over time"})]}),"\n",(0,r.jsxs)(s.li,{children:["DNA + RNA profiling and repeat testing favour ",(0,r.jsx)(s.strong,{children:"centralised, scalable sequencing platforms"})]}),"\n"]})]})]})}function u(e={}){const{wrapper:s}={...(0,t.R)(),...e.components};return s?(0,r.jsx)(s,{...e,children:(0,r.jsx)(d,{...e})}):d(e)}},8453:(e,s,n)=>{n.d(s,{R:()=>o,x:()=>l});var i=n(6540);const r={},t=i.createContext(r);function o(e){const s=i.useContext(t);return i.useMemo((function(){return"function"==typeof e?e(s):{...s,...e}}),[s,e])}function l(e){let s;return s=e.disableParentContext?"function"==typeof e.components?e.components(r):e.components||r:o(e.components),i.createElement(t.Provider,{value:s},e.children)}}}]);